Source comparison
MK-677 Dosage 10mg 15mg 25mg: Side-by-Side Comparison
Before selecting a dose tier, understand the physiological trade-offs across efficacy, side effects, and protocol sustainability. 10mg 60% 40–60 Mild (10–15% intake increase) Low. Rare unless pre-existing IR 2–3 16–24 weeks Best for long-duration studies prior
This comparison does not assign a generated winner or score.
- Before selecting a dose tier, understand the physiological trade-offs across efficacy, side effects, and protocol sustainability.
- 10mg
- 60%
- 40–60
- Mild (10–15% intake increase)
- Low. Rare unless pre-existing IR
- 2–3
- 16–24 weeks
- Best for long-duration studies prioritizing metabolic safety. Ideal for sleep research, geriatric models, or contexts where sustained administration outweighs peak GH output.
- 15mg
- 75–85%
- 60–90
- Moderate to high (20–30% increase)
- Moderate. Monitor fasting glucose biweekly
- 3–5
- 10–16 weeks
- Optimal anabolic dose for lean mass research. Delivers measurable nitrogen retention and recovery benefits without the glucose handling issues of 25mg. Standard choice for muscle preservation studies.
- 25mg
- 90–100%
- 100+
- Severe (40–50% surplus common)
- High. Fasting glucose rise 10–20 mg/dL, insulin sensitivity decline by week 4
- 6–8
- 6–8 weeks maximum
- Reserved for short-term protocols where maximal GH elevation justifies metabolic risk. Requires strict glucose monitoring. Not sustainable beyond 8 weeks in most models.
- The Bottom Line column reflects what matters most: dose selection must align with study duration and metabolic monitoring capacity. A 25mg protocol without weekly glucose panels is reckless; a 10mg protocol in a six-week acute recovery study is underdosed.